Erratum: Discovery and clinical introduction of first-in-class imipridone onc201 (Oncotarget. (2016) 7 (74380-74392) DOI: 10.18632/oncotarget.11814)

Joshua E. Allen; C. Leah; Varun V. Prabhu; Jessica Wagner; Jo Ishizawa; Neel Madhukar; Avital Lev; Marie Baumeister; Lanlan Zhou; Amriti Lulla; Martin Stogniew; Lee Schalop; Cyril Benes; Howard L. Kaufman; Richard S. Pottorf; B. Rao Nallaganchu; Gary L. Olson; Fahd Al-Mulla; Madeleine Duvic; Gen Sheng Wu; David T. Dicker; Mala K. Talekar; Bora Lim; Olivier Elemento; Wolfgang Oster; Joseph Bertino; Keith Flaherty; Michael L. Wang; Gautam Borthakur; Michael Andreeff; Mark Stein; Wafik S. El-Deiry

doi:10.18632/ONCOTARGET.28012

Erratum: Discovery and clinical introduction of first-in-class imipridone onc201 (Oncotarget. (2016) 7 (74380-74392) DOI: 10.18632/oncotarget.11814)

Joshua E. Allen, C. Leah, Varun V. Prabhu, Jessica Wagner, Jo Ishizawa, Neel Madhukar, Avital Lev, Marie Baumeister, Lanlan Zhou, Amriti Lulla, Martin Stogniew, Lee Schalop, Cyril Benes, Howard L. Kaufman, Richard S. Pottorf, B. Rao Nallaganchu, Gary L. Olson, Fahd Al-Mulla, Madeleine Duvic, Gen Sheng WuDavid T. Dicker, Mala K. Talekar, Bora Lim, Olivier Elemento, Wolfgang Oster, Joseph Bertino, Keith Flaherty, Michael L. Wang, Gautam Borthakur, Michael Andreeff, Mark Stein, Wafik S. El-Deiry

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

W.S.E-D. is a co-founder and shareholder of Oncoceutics, Inc. W.S.E-D. is fully compliant with institutional disclosure requirements and conflict of interest rules. Dr. Michael Andreeff is also a shareholder of Oncoceutics, Inc. Some of the additional authors are employees or shareholders at Oncoceutics, Inc.

Original language	English (US)
Pages (from-to)	2231
Number of pages	1
Journal	Oncotarget
Volume	12
Issue number	21
DOIs	https://doi.org/10.18632/ONCOTARGET.28012
State	Published - Oct 12 2021

ASJC Scopus subject areas

Oncology

MD Anderson CCSG core facilities

Flow Cytometry and Cellular Imaging Facility

Access to Document

10.18632/ONCOTARGET.28012

Cite this

Allen, J. E., Leah, C., Prabhu, V. V., Wagner, J., Ishizawa, J., Madhukar, N., Lev, A., Baumeister, M., Zhou, L., Lulla, A., Stogniew, M., Schalop, L., Benes, C., Kaufman, H. L., Pottorf, R. S., Rao Nallaganchu, B., Olson, G. L., Al-Mulla, F., Duvic, M., ... El-Deiry, W. S. (2021). Erratum: Discovery and clinical introduction of first-in-class imipridone onc201 (Oncotarget. (2016) 7 (74380-74392) DOI: 10.18632/oncotarget.11814). Oncotarget, 12(21), 2231. https://doi.org/10.18632/ONCOTARGET.28012

Allen, JE, Leah, C, Prabhu, VV, Wagner, J, Ishizawa, J, Madhukar, N, Lev, A, Baumeister, M, Zhou, L, Lulla, A, Stogniew, M, Schalop, L, Benes, C, Kaufman, HL, Pottorf, RS, Rao Nallaganchu, B, Olson, GL, Al-Mulla, F, Duvic, M, Wu, GS, Dicker, DT, Talekar, MK, Lim, B, Elemento, O, Oster, W, Bertino, J, Flaherty, K, Wang, ML , Borthakur, G , Andreeff, M, Stein, M & El-Deiry, WS 2021, 'Erratum: Discovery and clinical introduction of first-in-class imipridone onc201 (Oncotarget. (2016) 7 (74380-74392) DOI: 10.18632/oncotarget.11814)', Oncotarget, vol. 12, no. 21, pp. 2231. https://doi.org/10.18632/ONCOTARGET.28012

@article{b77a97d33bb041e9b89019bb908806cb,

title = "Erratum: Discovery and clinical introduction of first-in-class imipridone onc201 (Oncotarget. (2016) 7 (74380-74392) DOI: 10.18632/oncotarget.11814)",

abstract = "W.S.E-D. is a co-founder and shareholder of Oncoceutics, Inc. W.S.E-D. is fully compliant with institutional disclosure requirements and conflict of interest rules. Dr. Michael Andreeff is also a shareholder of Oncoceutics, Inc. Some of the additional authors are employees or shareholders at Oncoceutics, Inc.",

author = "Allen, {Joshua E.} and C. Leah and Prabhu, {Varun V.} and Jessica Wagner and Jo Ishizawa and Neel Madhukar and Avital Lev and Marie Baumeister and Lanlan Zhou and Amriti Lulla and Martin Stogniew and Lee Schalop and Cyril Benes and Kaufman, {Howard L.} and Pottorf, {Richard S.} and {Rao Nallaganchu}, B. and Olson, {Gary L.} and Fahd Al-Mulla and Madeleine Duvic and Wu, {Gen Sheng} and Dicker, {David T.} and Talekar, {Mala K.} and Bora Lim and Olivier Elemento and Wolfgang Oster and Joseph Bertino and Keith Flaherty and Wang, {Michael L.} and Gautam Borthakur and Michael Andreeff and Mark Stein and El-Deiry, {Wafik S.}",

year = "2021",

month = oct,

day = "12",

doi = "10.18632/ONCOTARGET.28012",

language = "English (US)",

volume = "12",

pages = "2231",

journal = "Oncotarget",

issn = "1949-2553",

publisher = "Impact Journals",

number = "21",

}

TY - JOUR

T1 - Erratum

T2 - Discovery and clinical introduction of first-in-class imipridone onc201 (Oncotarget. (2016) 7 (74380-74392) DOI: 10.18632/oncotarget.11814)

AU - Allen, Joshua E.

AU - Leah, C.

AU - Prabhu, Varun V.

AU - Wagner, Jessica

AU - Ishizawa, Jo

AU - Madhukar, Neel

AU - Lev, Avital

AU - Baumeister, Marie

AU - Zhou, Lanlan

AU - Lulla, Amriti

AU - Stogniew, Martin

AU - Schalop, Lee

AU - Benes, Cyril

AU - Kaufman, Howard L.

AU - Pottorf, Richard S.

AU - Rao Nallaganchu, B.

AU - Olson, Gary L.

AU - Al-Mulla, Fahd

AU - Duvic, Madeleine

AU - Wu, Gen Sheng

AU - Dicker, David T.

AU - Talekar, Mala K.

AU - Lim, Bora

AU - Elemento, Olivier

AU - Oster, Wolfgang

AU - Bertino, Joseph

AU - Flaherty, Keith

AU - Wang, Michael L.

AU - Borthakur, Gautam

AU - Andreeff, Michael

AU - Stein, Mark

AU - El-Deiry, Wafik S.

PY - 2021/10/12

Y1 - 2021/10/12

N2 - W.S.E-D. is a co-founder and shareholder of Oncoceutics, Inc. W.S.E-D. is fully compliant with institutional disclosure requirements and conflict of interest rules. Dr. Michael Andreeff is also a shareholder of Oncoceutics, Inc. Some of the additional authors are employees or shareholders at Oncoceutics, Inc.

AB - W.S.E-D. is a co-founder and shareholder of Oncoceutics, Inc. W.S.E-D. is fully compliant with institutional disclosure requirements and conflict of interest rules. Dr. Michael Andreeff is also a shareholder of Oncoceutics, Inc. Some of the additional authors are employees or shareholders at Oncoceutics, Inc.

UR - http://www.scopus.com/inward/record.url?scp=85118726659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85118726659&partnerID=8YFLogxK

U2 - 10.18632/ONCOTARGET.28012

DO - 10.18632/ONCOTARGET.28012

M3 - Comment/debate

C2 - 34676056

AN - SCOPUS:85118726659

SN - 1949-2553

VL - 12

SP - 2231

JO - Oncotarget

JF - Oncotarget

IS - 21

ER -

Erratum: Discovery and clinical introduction of first-in-class imipridone onc201 (Oncotarget. (2016) 7 (74380-74392) DOI: 10.18632/oncotarget.11814)

Abstract

ASJC Scopus subject areas

MD Anderson CCSG core facilities

Access to Document

Other files and links

Fingerprint

Cite this